This is much lower than the peak concentrations achieved in clinical trials after periodic administration of FGF21 analogues at supraphysiological doses.[58, 59] Consistently, some recent studies show that modulation of the translation velocity could be a better therapeutic strategy for the treatment of cystic fibrosis mutants and for some types of cancers.[60, 61] Further studies would be required to determine the feasibility and safety of this therapeutic approach. This evidence concerns the gene FGF21 and cancer.